Infected cells

The pathogenesis of AIDS (10,12,13) following HIV infection may be separated into primary and secondary effects. The primary effects are (/) quantitative and quahtative decreases in infected cells, ie, the T-lymphocytes (2) impaked cellular immunity (J) impaked immune surveillance and... 

Gradual diminution of 004 T-lymphocytes from the peripheral blood is the most consistent feature observed in HIV infection. Because the majority of 004 cells are T-helper lymphocytes, removal leads to deficiency of cellular immunity, which depends on T-helper cells to initiate cytotoxic T-ceU killing of vims-infected cells of cancer. The loss of immune surveillance leads to the appearance of viraHy induced tumors from unopposed clonal expansion of viraHy transformed cells. Furthermore, depletion of cellular immunity leads to exaggerated viral, fungal, and proto2oal infections. 

The deterrnination of the presence of reverse transcriptase in vims-infected cells can be done using labeled nucleotide triphosphates. Reverse transcriptase is an enzyme capable of synthesizing DNA from RNA and it is thought to play an important role in vims-mediated cell modification. This enzyme is also a marker enzyme for HIV, the vims impHcated in causing acquired immunodeficiency syndrome (AIDS). The procedure utilizes radiolabeled nucleotides with nonlabeled substrates to synthesize tagged DNA. The degree of radioactive incorporation reflects the reverse transcriptase activity. 

Thiosemicarba2ones have long been used as antiviral agents, principally against pox vimses of the vaccinia family. One compound of this series, the isatin derivative (6) C HgN OS, has been used prophylacticaHy to prevent outbreaks of smallpox in humans (10) and to inhibit the protein synthesis in poxvims-infected cells. The molecular mechanics relating to this property are still not known (11), though the binding of a metal ion may be a key factor... 

Amino-5-iodo-2, 5 -dideoxyuridine [56045-73-9] (13) C2H22IN2O4, was synthesized ia 1975 (27) and was found effective against herpes keratitis ia rabbits (28). This compound is markedly less cytotoxic than IdU, iadicating that it may have a safer and more specific mode of antiviral activity. A potential limitation of this group of nucleosides is their specificity, for they fail to inhibit all strains of herpes vimses. The specific antiviral activity of (13) is considered to be a result of the incorporation of the 5 -Ai-phosphate into both viral and host DNA in infected cells, but not into the DNA of normal cells. Phosphorylation of (13) occurs only in herpes vims-infected cells, brought about by a vims-induced thymidine kinase (29). 

BVdU is incorporated into DNA, but since it is phosphorylated specifically in the viraHy infected cell, incorporation is mainly confined to such cells. Evidence suggests that BVdU also inhibits the biosynthesis of HSV-1 glycoproteins, which may contribute to the inhibition of the HSV-1 vims (32). 

Ara-A is phosphorylated in mammalian cells to ara-AMP by adenosine kinase and deoxycytidine kinase. Further phosphorylation to the di- and triphosphates, ara-ADP and ara-ATP, also occurs. In HSV-1 infected cells, ara-A also is converted to ara-ATP. Levels of ara-ATP correlate directly with HSV rephcation. It has recently been suggested that ara-A also may exhibit an antiviral effect against adenovims by inhibiting polyadenylation of viral messenger RNA (mRNA), which may then inhibit the proper transport of the viral mRNA from the cell nucleus. 

The antiviral mechanism of action of acyclovir has been reviewed (72). Acyclovir is converted to the monophosphate in herpes vims-infected cells (but only to a limited extent in uninfected cells) by viral-induced thymidine kinase. It is then further phosphorylated by host cell guanosine monophosphate (GMP) kinase to acyclovir diphosphate [66341 -17-1], which in turn is phosphorylated to the triphosphate by unidentified cellular en2ymes. Acyclovir triphosphate [66341 -18-2] inhibits HSV-1 viral DNA polymerase but not cellular DNA polymerase. As a result, acyclovir is 300 to 3000 times more toxic to herpes vimses in an HSV-infected cell than to the cell itself. Studies have shown that a once-daily dose of acyclovir is effective in prevention of recurrent HSV-2 genital herpes (1). HCMV, on the other hand, is relatively uninhibited by acyclovir. 

The role of the viral neuraminidase, conversely, seems to be to facilitate the release of progeny virions from infected cells by cleaving sialic acid... 

Progeny vims particles then bud from patches of the infected cell s plasma membrane that contain both the viral hemagglutinin and neuraminidase. The viral envelopes therefore contain both viral membrane proteins but no cellular membrane proteins. 

Each precursor protein molecule is cleaved only once to generate one molecule of the coat protein, and catalytic activity is restricted to the precursor protein. Why is the coat protein itself catalytically inactive The structure of the coat protein shows that its C-terminus is bound in the active site cleft and thereby prevents other proteins entering the cleft and being cleaved. Tbis arrangement allows the precursor protein to fulfill its function to generate the coat protein and prevents the coat protein from destroying other proteins in the infected cell, including other coat proteins. 

Compounds prepared from naturally occurring nucleosides are of course more closely related to genetic material and may have a better chance of interacting with infected cells. Mercu-ration of the 2 -dcoxyuridine 113 leads to the organometallic derivative 114 reaction of that with ethylene in the presence dilithio palladium tetrachloride gives the alkylation product 115 this is reduced catalytically in situ. There is thus obtained the antiviral agent edoxudine (116) [25]. 

Infected Cells Infected cells are assumed to gradually, and linearly, approach the ill state as a function of the average degree of infection in their neighborhood. Define Sij t) as the average degree of infection of sites neighboring site (bi) at time ... 

An important safety issue of viral vectors is whether or not the recombinant viruses are able to replicate in the infected cells. Replication of viral vectors is unwanted in most gene-therapy approaches. Therefore, replication-defective vectors have been designed, which are able to perform only one initial infectious cycle within the target cell. In addition, replication-competent vectors have been designed, which are able to productively infect the target cell and to spread in the target tissue. 

With respect to targeting viral gene products expressed in virus-infected cells, it should be considered that infectious mammalian viruses may express inhibitors of RNAi similar to plant viruses. 

The infectious cycle of a (+)-strand RNA virus such as the hepatitis C virus differs by the fate of the viral RNA genome in the infected cell. Upon entry into the cell, the HCV genome is used as a messenger RNA to drive the synthesis of a large polyprotein precursor of about 3,000 residues [2]. The structural proteins are excised from the precursor by host cell signal peptidase. 

In contrast to retroviruses, proteolysis is an early event in the replication cycle of (+)-strand RNA viruses and both protease and polymerase inhibitors can be expected to halt the propagation of infectious viral particles from already infected cells. 

Rhinoviruses, which represent the single major cause of common cold, belong to the family of picornavimses that harbors many medically relevant pathogens. Inhibitors of the 3C protease, a cysteine protease, have shown good antiviral potential. Several classes of compounds were designed based on the known substrate specificity of the enzyme. Mechanism-based, irreversible Michael-acceptors were shown to be both potent inhibitors of the purified enzyme and to have antiviral activity in infected cells. 

Stuyver LJ, McBrayer TR, Thamish PM, Qark J, HoUecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie M-Y, Schinazi RE, Morrey JD, Inlander JL, Eurman PA, Otto MJ (2006) Inhibition of hepatitis C repUcon RNA synthesis by P-D-2 -deoxy-2 -fluoro-2 -C-methylcytidine a specific inhibitor of hepatitis C virus replication. Antiviral Chem Chemother 17 79-87 Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK (1992) A protein kinase homo-logue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 359 85... 

Saquinavir. SQV was first shown in vitro to have potent HIV-1 inhibition in acutely infected cells with an IC50 in the subnanomolar range and to inhibit viral maturation in chronically infected cells at 10 nM (Craig et al. 1991). Subsequently, clinical trials with SQV monotherapy in HIV-1 infected men at concentrations up to 600 mg three times a day for 16 weeks resulted in a decrease in HIV-1 RNA of 80% (0.71ogio) (Kitchen et al. 1995). These and other data facilitated SQV in becoming the first FDA-approved PI in December 1995. In its original formulation. 

---